Dr. Reddy's Laboratories announces the First-to-Market launch of the generic version of Ciprodex in US

USA: Dr. Reddy’s Laboratories Ltd today announced the launch of Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, a therapeutic equivalent generic version of Ciprodex® (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, approved by the U.S. Food and Drug Administration (USFDA).

Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions of Acute Otitis Media (AOM) in pediatric and Acute Otitis Externa (AOE) in pediatric, adult and elderly patients.

“We are pleased to launch this first-to-market generic product, illustrating our continued commitment to bring affordable generic medicines to market for patients,” says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories.

“At the same time, this product demonstrates that we are actively expanding the depth of our portfolio with our first otic suspension dosage form” he further added.

The Ciprodex® brand had U.S. sales of approximately $453 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.

Dr. Reddy’s Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, is available as 7.5 mL fill in a 10 mL bottle.